Prime Medicine
Prime Medicine raises $315M Series B at $1.85B valuation
Quick Facts
Prime Medicine: Series B Funding Round
Prime Medicine has successfully raised $315M in Series B funding, reaching a valuation of $1.85B.
Company Overview
Prime editing gene therapy
Funding Details
The Series B round was led by GV, with participation from F-Prime Capital, Westlake Village BioPartners, ARCH Venture Partners, Deerfield Management.
Company Information
- Headquarters: 800 Boylston Street, Boston, MA 02199
- Founded: 2019
- Employees: 250+
- Category: Biotech
Investment
Prime Medicine plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- GV: Verified investor in Series B
- F-Prime Capital: Verified investor in Series B
- Westlake Village BioPartners: Verified investor in Series B
- ARCH Venture Partners: Verified investor in Series B
- Deerfield Management: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...